Sarcoidosis
Recent clinical, regulatory, research and industry developments relating to this disease.
Immune mechanisms of granuloma formation in sarcoidosis and tuberculosis.
ERS clinical practice guidelines on treatment of sarcoidosis.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 4 clinical trials expected to report results, the earliest in Q4 2026.
- Q4 2026Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial
- Q4 2026Vitamin D Homeostasis in Sarcoidosis
- Q1 2027Evaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis : a Prospective, Randomized, Controlled Trial
- Q3 2027A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of a 12-week Administration of OATD-01, an Oral Inhibitor of Chitinase-1 (CHIT1), for the Treatment of Active Pulmonary Sarcoidosis (the KITE Study)
Clinical MilestonesViewHide
- 2026-09-03Vitamin D Homeostasis in SarcoidosisResults expected Q4 2026
- 2026-07-30A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of a 12-week Administration of OATD-01, an Oral Inhibitor of Chitinase-1 (CHIT1), for the Treatment of Active Pulmonary Sarcoidosis (the KITE Study)Results expected Q3 2027
- 2026-07-10Cardiac Sarcoidosis Multi-Center Randomized Controlled TrialResults expected Q4 2026
- 2026-04-24Evaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis : a Prospective, Randomized, Controlled TrialResults expected Q1 2027
- 2026-09-03ClinicalVitamin D Homeostasis in SarcoidosisResults expected Q4 2026
- 2026-07-30ClinicalA Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of a 12-week Administration of OATD-01, an Oral Inhibitor of Chitinase-1 (CHIT1), for the Treatment of Active Pulmonary Sarcoidosis (the KITE Study)Results expected Q3 2027
- 2026-07-10ClinicalCardiac Sarcoidosis Multi-Center Randomized Controlled TrialResults expected Q4 2026
- 2026-04-24ClinicalEvaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis : a Prospective, Randomized, Controlled TrialResults expected Q1 2027
- 2026-04-17ClinicalClinical Biomarkers of Disease Activity and Treatment Responses in Patients With CNS Sarcoidosis Treated With H.P. Acthar GelResults posted
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes5
- Sarcoidosis3
- Mycobacterium tuberculosis1
- Myocarditis1
- Quality of Life1
- Tuberculosis1
Leading journals3
- International journal of cardiology1
- The European respiratory journal1
- The Journal of clinical investigation1
Leading researchers8
- Antoniou K1
- Baughman RP1
- Bergh N1
- Björkenstam M1
- Bobbio E1
- Bollano E1
- Bonella F1
- Culver DA1
Affiliations (unnormalised)6
- Albany Medical College1
- Center for Interstitial and Rare Lung Diseases1
- Cleveland Clinic1
- Department of Clinical Pathology1
- Department of Clinical Physiology1
- Foundation for Sarcoidosis Research1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Reference
Authoritative identity, definition & identifiers.
An idiopathic systemic inflammatory granulomatous disorder comprised of epithelioid and multinucleated giant cells with little necrosis. It usually invades the lungs with fibrosis and may also involve lymph nodes, skin, liver, spleen, eyes, phalangeal bones, and parotid glands.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.